1700 Owens Street
About Unity Biotechnology
Unity Biotechnology is a drug discovery start-up dedicated to designing therapeutics that prevent, halt, or reverse diseases of aging. We are creating medicines that lengthen healthspan, the amount of time people live in good health.
Backed by ARCH Venture Partners and Venrock, Unity has been working for over four years to develop senolytic drugs — drugs that clear senescent cells from the body while leaving normal cells unaffected. Unity has demonstrated in animal models that clearing senescent cells restores normal tissue function, thereby reversing or preventing many age-related pathologies, including osteoarthritis, atherosclerosis, eye diseases and kidney diseases. Our mission is to build a future in which these diseases no longer affect people’s daily lives as they grow older — a future in which people stay healthy and mobile long into old age.
Unity’s world-class management team has collectively moved 91 therapeutic candidates into human clinical trials and is responsible for the creation of 13 FDA-approved medicines. Unity is located in the San Francisco Bay area and is seeking to hire experienced individuals to help guide our vision toward reality.
13 articles with Unity Biotechnology
China’s Hillhouse Capital Group, an equity investment firm, has a new fund, Hillhouse Fund IV, with $10.6 billion ready to invest.
After Unity Biotechnology chief executive officer Keith Leonard was on CNBC’s “Power Lunch,” touting the company’s therapeutic approach to longevity and aging, company shares soared almost 18 percent.
In another example of companies focused on aging-related diseases, Elevian launched with $5.5 million in seed funding. Elevian’s founders came out of Stanford and then Harvard, focused on regenerative effects of “young blood.”
Pharma and biotech companies across the globe continued to expand and reshape their leadership teams with new hires this past week. BioSpace collected several announced leadership appointments, which includes new chief executive officers, new members to boards of directors and more.
A company focused on aging-related ailments is looking to infuse new life into its coffers through an initial public offering. Unity Biotechnology is seeking to raise $85 million in the IPO as it takes its lead candidate into the clinic later this year.
Proceeds to Support Advancement of Pipeline into Clinical Studies
Dr. Lacey brings to UNITY more than 30 years of experience in medical research, including a 17-year tenure at Amgen leading research across multiple disease areas.
Ascentage Pharma And Unity Biotechnology Announce Collaboration For The Development Of Senolytic Healthspan Therapies
Emerging from Stealth Mode to Prevent Diseases of Aging, Unity Biotechnology to Double Hiring in Bay Area